Atsena Therapeutics

Atsena Therapeutics is a clinical-stage gene therapy company committed to reversing or preventing blindness by transforming the lives of patients through genetic medicine. The company is currently conducting a Phase I/II clinical trial to evaluate a potential therapy for one of the most common causes of childhood blindness. Its additional leading preclinical asset pipeline is enabled by an adeno-associated virus (AAV) technology platform, specifically designed to overcome the challenges posed by inherited retinal diseases, with an approach guided by the specific needs of each patient. Founded by pioneers in the field of ocular gene therapy, Atsena has licensing, research, and manufacturing partnerships with the University of Florida and is headquartered in North Carolina's Research Triangle area, a region rich in gene therapy expertise.